Keppra

Levetiracetam, the active ingredient in Keppra, is an anticonvulsant presented as an injection for intravenous use. It treats partial seizures, generalized tonic-clonic seizures and myoclonic seizures in patients with epilepsy and is approved in the European Union.

GNH USA supplies Keppra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures consistent quality, regulatory compliance and reliable logistics for global markets. Keppra is available in multiple vial sizes to meet diverse clinical needs and is stored under controlled temperature conditions.

Levetiracetam is an anticonvulsant used to manage various seizure types in epilepsy. - Partial seizures: Reduces the frequency of focal onset seizures. - Generalized tonic-clonic seizures: Controls convulsive seizures and decreases recurrence. - Myoclonic seizures: Decreases brief shock-like muscle jerks associated with myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dizziness: sensation of lightheadedness or unsteadiness. - Fatigue: feeling unusually tired or low energy. - Headache: mild to moderate head pain. - Irritability: increased mood swings or agitation. - Nausea: upset stomach or urge to vomit. - Somnolence: drowsiness or sleepiness. Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens-Johnson syndrome: serious skin disorder with blistering. - Mood changes: depression or suicidal thoughts. - Hematologic abnormalities: low blood cell counts. - Hepatic dysfunction: elevated liver enzymes or liver injury.

When prescribing levetiracetam, clinicians should consider several safety and handling precautions. - Renal function: adjust dose in patients with impaired renal clearance. - Pregnancy: category B, use only if benefit outweighs risk. - Concomitant CNS depressants: monitor for enhanced sedation. - Psychiatric history: observe for mood alterations or aggression. - Discontinue gradually: avoid abrupt cessation to reduce seizure recurrence. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam may interact with other medicines, requiring careful management. Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenytoin: may decrease efficacy of levetiracetam. - Phenobarbital: can lower levetiracetam concentrations. Moderate Interactions (Monitor Closely): - Alcohol: may increase central nervous system depression. - Other antiepileptics: potential additive sedation. - Oral contraceptives: possible reduced effectiveness of hormonal contraception.